Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55 USD | +2.02% | -1.10% | -12.06% |
18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 407
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Collaboration
99.7
%
| 0 | 36.4 % | 370 | 99.7 % | +84,762.39% |
Grant
0.3
%
| 1 | 63.6 % | 1 | 0.3 % | +58.27% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switzerland and United States
100.0
%
| 1 | 100.0 % | 371 | 100.0 % | +30,885.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 01/15/01 |
Raju Prasad
DFI | Director of Finance/CFO | 40 | 14/23/14 |
Stephen Kennedy
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/19/01 |
Jonathan Terrett
CTO | Chief Tech/Sci/R&D Officer | - | 28/17/28 |
Susan Kim
IRC | Investor Relations Contact | - | - |
Alex Harding
PRN | Corporate Officer/Principal | - | 05/23/05 |
Human Resources Officer | - | 01/16/01 | |
Jim Kasinger
LAW | General Counsel | 52 | 01/17/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
BRD | Director/Board Member | 66 | 11/20/11 |
Simeon George
BRD | Director/Board Member | 46 | 29/15/29 |
Ali Behbahani
BRD | Director/Board Member | 47 | 01/15/01 |
Maria Fardis
BRD | Director/Board Member | 56 | 09/22/09 |
Katherine High
BRD | Director/Board Member | 72 | 11/19/11 |
John Greene
BRD | Director/Board Member | 58 | 11/19/11 |
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 01/15/01 |
Director/Board Member | 61 | 10/21/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 85,053,407 | 83,305,141 ( 97.94 %) | 170,316 ( 0.2002 %) | 97.94 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.06% | 4.58B | |
+2.17% | 42.75B | |
+47.81% | 41.61B | |
+12.30% | 41.34B | |
-12.36% | 26.59B | |
+8.53% | 25.49B | |
-23.57% | 18.12B | |
+30.80% | 12.24B | |
-1.85% | 11.76B | |
+8.54% | 11B |
- Stock Market
- Equities
- CRSP Stock
- Company CRISPR Therapeutics AG